Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model

Favipiravir has broad-spectrum antiviral activity against a variety of RNA viruses. Here the authors investigate the safety, pharmacokinetics and anti-SARS-CoV-2 efficacy of different drug dosage in the a Syrian hamster model of infection and, combined with genetic analyses, they show that Favipirav...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jean-Sélim Driouich, Maxime Cochin, Guillaume Lingas, Grégory Moureau, Franck Touret, Paul-Rémi Petit, Géraldine Piorkowski, Karine Barthélémy, Caroline Laprie, Bruno Coutard, Jérémie Guedj, Xavier de Lamballerie, Caroline Solas, Antoine Nougairède
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Q
Acceso en línea:https://doaj.org/article/28b65fe72e8643d09a5316e736cd7471
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Favipiravir has broad-spectrum antiviral activity against a variety of RNA viruses. Here the authors investigate the safety, pharmacokinetics and anti-SARS-CoV-2 efficacy of different drug dosage in the a Syrian hamster model of infection and, combined with genetic analyses, they show that Favipiravir at high doses decrease viral infectivity while inducing the emergence of mutations in viral genomes, decreasing fitness.